Subscribe
shutterstock_752858728_casimiro_pt
Casimiro PT / Shutterstock.com
22 April 2021Big PharmaAlex Baldwin

Supreme Court hears Minerva v Hologic arguments

The US Supreme Court heard oral arguments in Minerva Surgical v Hologic yesterday to discuss the potential abandoning of assignor estoppel.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Breaking: SCOTUS says inventors can challenge their patents, but imposes limits
29 June 2021   The US Supreme Court has upheld the doctrine of assignor estoppel in a dispute between Minerva and Hologic but has narrowed its scope.
Big Pharma
Minerva: less risk for inventors, more work for the courts
1 July 2021   The US Supreme Court opinion in Minverva v Hologic means that inventors will now have a far narrower scope to be able to challenge the validity of their own patents in defence proceedings—a decision that was controversial among the judges.
Medtech
Fed Circuit rejects Minerva patent invalidation bid
12 August 2022   Hologic patent invented by Minerva’s founder cannot be invalidated | Patent in dispute concerns device used to treat uterine bleeding | US Court of Appeals.


Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024

Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024
Unified Patent Court
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute
26 September 2024
Unified Patent Court
Interview: Klaus Grabinski, UPC Court of Appeal president
24 September 2024
Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024
Unified Patent Court
Does the UPC offer a fresh take on patent validity?
5 September 2024

More on this story

Americas
Breaking: SCOTUS says inventors can challenge their patents, but imposes limits
29 June 2021   The US Supreme Court has upheld the doctrine of assignor estoppel in a dispute between Minerva and Hologic but has narrowed its scope.
Big Pharma
Minerva: less risk for inventors, more work for the courts
1 July 2021   The US Supreme Court opinion in Minverva v Hologic means that inventors will now have a far narrower scope to be able to challenge the validity of their own patents in defence proceedings—a decision that was controversial among the judges.
Medtech
Fed Circuit rejects Minerva patent invalidation bid
12 August 2022   Hologic patent invented by Minerva’s founder cannot be invalidated | Patent in dispute concerns device used to treat uterine bleeding | US Court of Appeals.

More on this story

Americas
Breaking: SCOTUS says inventors can challenge their patents, but imposes limits
29 June 2021   The US Supreme Court has upheld the doctrine of assignor estoppel in a dispute between Minerva and Hologic but has narrowed its scope.
Big Pharma
Minerva: less risk for inventors, more work for the courts
1 July 2021   The US Supreme Court opinion in Minverva v Hologic means that inventors will now have a far narrower scope to be able to challenge the validity of their own patents in defence proceedings—a decision that was controversial among the judges.
Medtech
Fed Circuit rejects Minerva patent invalidation bid
12 August 2022   Hologic patent invented by Minerva’s founder cannot be invalidated | Patent in dispute concerns device used to treat uterine bleeding | US Court of Appeals.

More features

President Trump 2.0: Five major areas to watch
Startup CFO’s betrayal is a lesson in preparing for the worst
Sandoz lands reduced antitrust award of $70m
New president’s to-do list: Patent bills, non-competes, USPTO director?
Sanofi subsidiary fends off $450m trade secrets case
Regulatory expert joins White & Case
Teva faces $500m fine for antitrust breaches over MS drug
UK Budget: A missed opportunity?